Gerard R.

Managing Specialist Programs that, amongst other aspects, involve complex authorities for Medicare/PBS approvals in the ophthalmology, cardiology and respiratory therapeutic areas.

Part-Time role with responsibility for the marketing and sales of the PBS Approved 'Ready to use' - RTU presentation of Jetrea (ocriplasmin), a pharmacological vitreolysis treatment for Vitreomacular Traction (VMT) and Macula Hole (MH).

Responsible for the marketing and re-launch of a PBS Approved pharmacological treatment for Vitreomacular Traction (VMT) and Macula Hole (MH) into the Australian/New Zealand market with the release of the 'Ready to use' - RTU presentation of the product in 2019.

Commercialisation and development of products for the medical and pharmaceutical industries; data conversions for medical centres: IRx (Integrated Prescriber’s Exchange) - streamlined digital authority portal, also providing stock, diary, script and medication management as well as pharmacy integration for specialists prescribing high value medications. AUTODOSE - precision opioid substitution dispensing management MEDLedger - precision electronic drugs register, both on premise and 'in the cloud' AQUADOSE - antibiotic liquid volume expansion automation; VAXGUARD - 24/7 fully-automated temperature monitoring protection for pharmacies, medical centres, aged care facilities. DATA CONVERSIONS - conversion of data for medical centres and clinics from one brand of software to another using our unique data conversion methodology; we stand behind the integrity of the data we convert.

Responsible for business development and sales of Lucentis (ranibizumab) for multiple retina disease conditions such as wAMD, DME, RVO for a Queensland Territory as well as continuing on with sales of Jetrea (ocriplasmin)for VMT & MH on a National basis. Awarded President's Club in 2017 for overall sales contribution across prior year.

Launched Jetrea (ocriplasmin) the pharmacological vitreolysis treatment for Vitreomacular Traction (VMT) and Macula Holes (MH) with responsibility for sales across Australia and New Zealand prior to PBS or funding availability in both markets. Once PBS was achieved in Australia sales in 1st month equalled total sales of prior year.

Joined as Northern Region Representative selling the Glaucoma and Ocular Surface Disease product portfolio and within 2 months was asked to take on the entire state of Queensland. During this period launched 1 new glaucoma product which achieved fastest growth across the country. Re-launched 2 existing glaucoma products that were re-introduced with a new gentler preservative and increased overall Queensland market-share with new Team Member. During this period also launched multiple Ocular Surface Disease/Dry Eye products to the Queensland market-place; all of which gained rapid uptake and significant market share, again in collaboration with my Team colleague.

New business sales and account management of practice and clinical management software package to specialists

Joined initially as Membership Officer and within 2 months was offered the position of Marketing & Membership Manager. During the time with AMAQ increased the number of medical student members, who are the future doctors; also maintained significant funding from sponsorship partners and members by improving the cash flow of member fees in conjunction with a strong team.

Initially joined in a 12 month contract position responsible for the sales of a vaccine and mixed therapeutic pharmaceutical portfolio. Offered a permanent position and during the subsequent 5 years launched the first vaccine for HPV exceeding target expectations; over-achieved in sales in the areas of men's health, dermatology and emergency medicine.